RxDoctor Payments Data

Janna Chen

Optometrist · Staten Island, NYNPI 1003923509

Payments from drug & device makers

$3,122in general payments, 2019–2025

Across 141 payments — averaging $22.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sight Sciences, Inc.$593
  • Dompe US, Inc.$314
  • Alcon$263
  • Sun Pharmaceutical Industries Inc.$257
  • Novartis$252
  • Harrow Eye, LLC$251
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$3,122100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,122 in reported general payments places this provider in the 85th percentile of 2,743 optometrist providers in New York.

See all optometrist providers in New York

Medicare billing

Part B allowed, 2024
$27,258
Medicare patients
116
Services billed
328

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine80$97,576
XiidraLifitegrast24$31,283
Cyclosporine56$26,490
LumiganBimatoprost21$13,470
Travatan ZTravoprost17$6,249
SimbrinzaBrinzolamide/Brimonidine Tart18$5,168
CombiganBrimonidine Tartrate/Timolol11$4,758
Travoprost14$3,535
Brimonidine Tartrate28$3,253
Timolol Maleate54$2,065
Latanoprost207$2,058
Azelastine Hcl79$1,910
Prednisolone Acetate53$1,853
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat89$1,765
Loteprednol Etabonate12$1,587

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$95$115,803112 claims
Bausch & Lomb Americas Inc.Xiidra$232$31,28324 claims
NovartisTravatan Z$252$6,24917 claims
AlconSimbrinza$263$5,16818 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$66$1,58712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,743 optometrist providers in New York.

Other optometrist in Staten Island

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →